entertainment -WSS

entertainment

author：Wikipedia 2025-10-01 21:48:08 - browse：15

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Elevance PBM president out as customers face prescription chaos

WSS

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

UnitedHealth CEO's Medicaid comments send insurer stocks diving

STAT Summit: GSK CEO on pharma giant's new direction

Illumina board agrees to spin off Grail, as divestment plans proceed

ASCO Daily Recap: CAR

Illumina board agrees to spin off Grail, as divestment plans proceed

focus

entertainment

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The explosion of genetic testing requires a new approach

23andMe had bad news about my health. I wish a person had delivered it

BD to buy Edwards patient monitoring unit for $4.2 billion

23andMe had bad news about my health. I wish a person had delivered it

Researchers explore possible ties between long Covid, menopause

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Illumina board agrees to spin off Grail, as divestment plans proceed

Trump demands the U.S. pay no more for drugs than other countries … again

Fight over Supreme Court dialysis ruling puts kidney patients at risk

hotspot

FDA approves Moderna’s RSV vaccine, its second licensed product

Fight over Supreme Court dialysis ruling puts kidney patients at risk

First Opinion Podcast: Long Covid needs a new approach

BD to buy Edwards patient monitoring unit for $4.2 billion

Senators tussle over abortion against the backdrop of a presidential campaign

UnitedHealth’s board chair also owns a personal investment firm

Wikipedia

hotspot

knowledge

hotspot